No connection

Search Results

ABBV vs CAH

ABBV
AbbVie Inc.
NEUTRAL
Price
$219.26
Market Cap
$387.52B
Sector
Healthcare
AI Confidence
68%
CAH
Cardinal Health, Inc.
NEUTRAL
Price
$199.85
Market Cap
$47.03B
Sector
Healthcare
AI Confidence
75%

Valuation

P/E Ratio
ABBV
163.63
CAH
28.76
Forward P/E
ABBV
15.42
CAH
17.25
P/B Ratio
ABBV
-146.66
CAH
-16.35
P/S Ratio
ABBV
6.5
CAH
0.19
EV/EBITDA
ABBV
15.27
CAH
13.98

Profitability

Gross Margin
ABBV
71.46%
CAH
3.69%
Operating Margin
ABBV
35.5%
CAH
1.23%
Profit Margin
ABBV
4.0%
CAH
0.68%
ROE
ABBV
137.96%
CAH
--
ROA
ABBV
9.59%
CAH
3.5%

Growth

Revenue Growth
ABBV
9.1%
CAH
18.8%
Earnings Growth
ABBV
-88.7%
CAH
19.4%

Financial Health

Debt/Equity
ABBV
--
CAH
--
Current Ratio
ABBV
0.72
CAH
0.91
Quick Ratio
ABBV
0.47
CAH
0.38

Dividends

Dividend Yield
ABBV
3.05%
CAH
1.02%
Payout Ratio
ABBV
490.15%
CAH
29.32%

AI Verdict

ABBV NEUTRAL

The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.

Strengths
High operating margin (35.50%) indicating strong pricing power and cost control
Consistent revenue growth (9.10% YoY) outpacing sector average
Strong track record of earnings surprises (22 out of 25 quarters beat estimates)
Risks
Extremely high P/E ratio (163.63) vs forward P/E (15.42), suggesting potential overvaluation on trailing basis
Earnings growth collapsing (YoY: -88.70%, Q/Q: -88.10%) indicating severe profitability deterioration
Unsustainable dividend payout ratio (490.15%) threatening dividend security
CAH NEUTRAL

Cardinal Health presents a dichotomy of strong growth and fragile liquidity, anchored by a stable Piotroski F-Score of 4/9. While the company exhibits impressive YoY revenue and earnings growth (~19%) and consistently beats analyst estimates, its operational health is hampered by razor-thin profit margins (0.68%) and a concerning current ratio of 0.91. The stock is trading slightly below its intrinsic value of $205.03, but bearish insider activity and a 0/100 technical trend suggest immediate headwinds despite a 'strong_buy' analyst consensus.

Strengths
Strong YoY revenue growth of 18.80%
Consistent earnings beat track record over 25 quarters
Significant forward P/E compression (from 28.76 to 17.25)
Risks
Extremely thin profit margins (0.68%) leave little room for error
Liquidity risk indicated by a Quick Ratio of 0.38
Current Ratio below 1.0 (0.91) suggests potential short-term obligations pressure

Compare Another Pair

ABBV vs CAH: Head-to-Head Comparison

This page compares AbbVie Inc. (ABBV) and Cardinal Health, Inc. (CAH) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile